Automated Adverse Event Reporting in Pharmaceuticals with AI

Introduction

This workflow outlines the automated process for collecting, validating, and reporting adverse events (AEs) in the pharmaceutical industry. By integrating AI-driven tools at various stages, the workflow aims to enhance efficiency, accuracy, and regulatory compliance in adverse event reporting.

1. Data Collection and Intake

The process begins with the collection of adverse event (AE) data from various sources:

• Electronic health records (EHRs)
• Clinical trial databases
• Spontaneous reporting systems
• Literature reports

AI-driven tools can enhance this step by:

• Utilizing natural language processing (NLP) to extract relevant information from unstructured text in medical records or literature.
• Employing machine learning algorithms to identify potential adverse events that may have been overlooked in manual reporting.

Example AI tool: IBM Watson for Drug Safety, which uses NLP to scan literature and identify potential safety signals.

2. Data Validation and Preprocessing

The collected data is validated for completeness and accuracy, followed by preprocessing for analysis:

• Checking for required fields (patient information, drug details, event description)
• Standardizing terminology using dictionaries such as MedDRA

AI can enhance this step by:

• Automatically mapping free text descriptions to standardized terms.
• Identifying and flagging potential data quality issues.

Example AI tool: Linguamatics NLP platform, which can extract and normalize medical concepts from various data sources.

3. Case Assessment and Prioritization

Cases are assessed for seriousness and prioritized for review:

• Determining if the case meets criteria for expedited reporting.
• Assigning priority based on event severity and unexpectedness.

AI can improve this process by:

• Predicting case seriousness based on historical data.
• Automatically triaging cases for appropriate review levels.

Example AI tool: Medidata Rave Detect, which uses machine learning to identify potential safety signals and prioritize cases.

4. Narrative Generation

This is where AI for content generation can have the most significant impact:

• Automatically drafting the initial narrative based on structured and unstructured data.
• Ensuring all relevant information is included in a logical flow.

AI-driven narrative generation can:

• Create human-readable narratives that adhere to regulatory guidelines.
• Maintain consistency across reports while adapting to case-specific details.

Example AI tool: Arria NLG Platform, which uses natural language generation to create human-like narratives from complex data.

5. Medical and Scientific Review

Trained professionals review the generated narratives:

• Assessing medical accuracy and completeness.
• Incorporating clinical judgment and interpretation.

AI can assist reviewers by:

• Highlighting potential inconsistencies or missing information.
• Suggesting relevant medical literature or similar cases for context.

Example AI tool: Molecular Health’s MH Guide, which provides AI-driven clinical decision support and literature analysis.

6. Quality Control and Approval

The narratives undergo final quality checks before approval:

• Ensuring compliance with regulatory requirements.
• Verifying consistency with source data.

AI can enhance this step by:

• Automatically checking for regulatory compliance.
• Comparing narratives against source data to flag discrepancies.

Example AI tool: ArisGlobal’s LifeSphere MultiVigilance, which includes AI-driven quality control features.

7. Submission and Distribution

Approved reports are submitted to regulatory authorities and distributed to relevant stakeholders:

• Generating submission-ready documents in required formats.
• Tracking submission deadlines and confirmations.

AI can improve this process by:

• Automating the creation of submission packages.
• Predicting optimal submission timing based on regulatory requirements and workload.

Example AI tool: Veeva Vault Safety, which includes AI-enhanced reporting and submission management features.

8. Continuous Learning and Improvement

The system continuously learns from feedback and outcomes:

• Updating AI models based on reviewer edits and regulatory feedback.
• Identifying trends and patterns in adverse event reporting.

This step ensures ongoing improvement in the accuracy and efficiency of the entire process.

By integrating these AI-driven tools throughout the workflow, pharmaceutical companies can significantly enhance the speed, accuracy, and consistency of adverse event report generation. This not only improves regulatory compliance but also contributes to better pharmacovigilance and patient safety.